Sacituzumab Govitecan In TNBC
NCT04230109
This study is recruiting at 4 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: Sacituzumab govitecan (SG) Pembrolizumab (combination therapy with SG)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Invasive Breast Cancer
- Triple Negative Breast Cancer
- ER-Negative Breast Cancer
- PR-Negative Breast Cancer
- HER2-negative Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- July 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 4
- Dana Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital · Boston, MA
- Massachusetts General Hospital - North Shore Cancer Center · Danvers, MA
- Massachusetts General Hospital at Newton-Wellesley Hospital · Newton, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.